1620 INVESTMENT ADVISORS, INC.
Position in VRTX — Vertex Pharmaceuticals Inc / Ma
CIK 1907281
PLYMOUTH, MA
Position in VRTX
as of Jun 30, 2026
· filed Jul 14, 2026
Position Value
$92,888
+$14,744 QoQ
Shares Held
187
+6.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#1,480
of 1,735 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 50%
Shared 0%
None 50%
Common Shares in VRTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 20261620 INVESTMENT ADVISORS, INC. holds $527,185 across 9 Biotechnology names. VRTX ranks #3 (17.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TGTX |
Tg Therapeutics, Inc.
|
3,735 | $205,200 | |
| 2 | TARS |
Tarsus Pharmaceuticals, Inc.
|
1,721 | $108,319 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
This page
|
187 | $92,888 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
122 | $36,725 | |
| 5 | NTLA |
Intellia Therapeutics, Inc.
|
1,300 | $21,996 | |
| 6 | ARQT |
Arcutis Biotherapeutics, Inc.
|
711 | $18,642 | |
| 7 | SVRA |
Savara Inc
|
3,000 | $18,480 | |
| 8 | PHVS |
Pharvaris N.V.
|
520 | $17,981 |
All Filings in VRTX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $92,888 | 187 | Shares | Sole | 2026-07-14 | |
| 2026-03-31 | $78,144 | 175 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $80,698 | 178 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $69,711 | 178 | Shares | Sole | 2025-10-07 | |
| 2025-06-30 | $80,581 | 181 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $88,722 | 183 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $71,680 | 178 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $81,854 | 176 | Shares | Sole | 2024-10-25 | |
| 2024-06-30 | $79,213 | 169 | Shares | Sole | 2024-07-23 | |
| No filing history on record for this holder in this stock. | ||||||